G007-LK

• CAT Number: I001470
• CAS Number: 1380672-07-0
• Molecular Formula: C25H16ClN7O3S
• Molecular Weight: 529.96
• Purity: ≥95%
• Synonyms: G007LK; G007LK; G007 LK; (E)-4-(5-(2-(4-(2-chlorophenyl)-5-(5-(methylsulfonyl)pyridin-2-yl)-4H-1,2,4-triazol-3-yl)vinyl)-1,3,4-oxadiazol-2-yl)benzonitrile
• Target: tankyrase
• Solubility: DMSO: ≥ 30 mg/mL
• Storage: Store at -20°C
• IC50: 46 nM/23 nM (TNKS1/TNKS2)
• IUPAC Name: 4-[5-[(E)-2-[4-(2-chlorophenyl)-5-(5-methylsulfonylpyridin-2-yl)-1,2,4-triazol-3-yl]ethenyl]-1,3,4-oxadiazol-2-yl]benzonitrile
• InChI: InChI=1S/C25H16ClN7O3S/c1-37(34,35)18-10-11-20(28-15-18)24-31-29-22(33(24)21-5-3-2-4-19(21)26)12-13-23-30-32-25(36-23)17-8-6-16(14-27)7-9-17/h2-13,15H,1H3/b13-12+
• InChIKey: HIWVLHPKZNBSBE-OUKQBFOZSA-N
• SMILES: CS(=O)(=O)C1=CN=C(C=C1)C2=NN=C(N2C3=CC=CC=C3Cl)C=CC4=NN=C(O4)C5=CC=C(C=C5)C#N

G007-LK(CAT: I001470) is a selective inhibitor of the LSD1 (lysine-specific demethylase 1) enzyme, which plays a key role in epigenetic regulation by removing methyl groups from histones. Inhibition of LSD1 by G007-LK can reverse the epigenetic silencing of tumor suppressor genes, making it a promising compound for cancer treatment. It has shown efficacy in various preclinical models of hematologic malignancies, particularly acute myeloid leukemia (AML), and is being investigated for its potential in epigenetic cancer therapy.